OmniAb Inc.
$ 1.73
1.17%
24 Feb - close price
- Market Cap 246,164,000 USD
- Current Price $ 1.73
- High / Low $ 1.78 / 1.72
- Stock P/E N/A
- Book Value 1.93
- EPS -0.59
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.22 %
- 52 Week High 3.60
- 52 Week Low 1.22
About
OmniAb Inc. is a biotechnology firm at the forefront of antibody development, utilizing its proprietary OmniAb platform to create fully human therapeutic antibodies. This innovative technology facilitates the discovery and optimization of high-quality therapeutics that address a range of diseases. With a strategic focus on partnerships and collaborations, OmniAb seeks to streamline drug development processes and expedite the delivery of cutting-edge treatments to the market. Boasting a seasoned management team and a promising pipeline, the company is well-positioned to harness substantial opportunities within the expanding biopharmaceutical landscape.
Analyst Target Price
$7.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-06 | 2025-05-07 | 2025-03-18 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.14 | -0.15 | -0.17 | -0.12 | -0.16 | -0.13 | -0.19 | -0.14 | -0.16 | -0.15 | -0.08 | 0.07 |
| Estimated EPS | -0.13 | -0.13 | -0.1667 | -0.0967 | -0.14 | -0.17 | -0.16 | -0.15 | -0.14 | -0.12 | -0.03 | 0.02 |
| Surprise | -0.01 | -0.02 | -0.0033 | -0.0233 | -0.02 | 0.04 | -0.03 | 0.01 | -0.02 | -0.03 | -0.05 | 0.05 |
| Surprise Percentage | -7.6923% | -15.3846% | -1.9796% | -24.0951% | -14.2857% | 23.5294% | -18.75% | 6.6667% | -14.2857% | -25% | -166.6667% | 250% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OABI
2026-02-24 12:52:00
OmniAb, Inc. (NASDAQ: OABI) announced its participation at the Leerink Global Healthcare Conference, scheduled for March 8-11, 2026, in Miami. Management will present a corporate overview on March 10th and hold one-on-one meetings with registered investors. The company specializes in licensing advanced discovery research technology to enable the development of next-generation therapeutics using its proprietary OmniAb platform.
2026-02-20 01:57:09
OmniAb, Inc. (NASDAQ: OABI) will release its financial results for the quarter and year ending December 31, 2025, after the U.S. financial markets close on Wednesday, March 4, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss these results and provide business updates.
2026-02-19 12:58:21
OmniAb, Inc. (NASDAQ: OABI) announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the U.S. financial markets close on Wednesday, March 4, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern time to discuss the results and provide business updates. A live and replay webcast with slides will also be available for interested parties.
2026-02-19 01:27:40
OmniAb director Charles Berkman sold 9,673 shares for $16,540.83, reducing his stake by 2.4%. This sale is part of broader insider selling activity from the CEO and CFO, while institutional ownership remains high at 72.08%. The stock trades near $1.71, and analyst ratings are mixed, with a "Moderate Buy" consensus target of $6.67 contrasting with a Weiss "sell" rating.
2026-02-19 01:27:40
OmniAb CEO Matthew Foehr sold 30,843 shares of OABI stock, valued at over $52,000, reducing his stake by 0.70%. The biotech company's stock trades around $1.71, with mixed analyst ratings and high institutional ownership. Other executives and a director also recently sold shares.
2026-02-19 01:27:40
OmniAb (NASDAQ:OABI) CFO Kurt Gustafson sold 9,301 shares of the company's stock for $15,904.71 on February 18, 2026, reducing his stake by 3.34%. This sale is part of a broader pattern of insider selling by the CEO and a director around the same time, despite "Moderate Buy" analyst ratings and increased institutional ownership. The stock is currently trading around $1.71, below its 50-day and 200-day simple moving averages.
